ISRCTN09480239已完成1 期
A double-blind, placebo controlled, phase I study to assess safety, tolerability and pharmacokinetics of single and multiple ascending oral doses of GIC-1001 in normal healthy volunteers
gIcare Pharma Inc (Canada)0 个研究点目标入组 80 人开始时间: 2012年12月11日最近更新:
适应症
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 发起方
- 入组人数
- 80
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 性别
- All
入选标准
- •1. Male or female volunteer
- •2. A female volunteer must meet one of the following criteria:
- •2.1. Participant is of childbearing potential and agrees to use one of the accepted contraceptive regimens from the screening visit until 2 months after the last drug administration. Additionally, if the participant is using systemic contraceptives, she must use an additional form of acceptable contraception from first drug administration until 2 months after the last drug administration. OR
- •2.2. Participant is of non-childbearing potential, defined as a female who had had a hysterectomy or tubal ligation, is clinically considered infertile or is in a menopausal state (at least 1 year without menses)
- •3. A male volunteer with sexual partners who are pregnant, possibly pregnant, or who could become pregnant must meet the following criterion: Participant agrees to use one of the accepted contraceptive regimens from first drug administration until 3 months after the last drug administration. An acceptable method of contraception includes one of the following: Abstinence from heterosexual intercourse or condom with spermicide
- •4. Volunteer aged of at least 18 years but not older than 50 years
- •5. Volunteer with a body mass index (BMI) greater than or equal to 18.50 and below 30 kg/m2
- •6. Non- or ex-smokers. An ex-smoker is defined as someone who completely stopped smoking for at least 6 months before day 1 of this study
- •7. Clinical laboratory values within the laboratory's stated normal range; if not within this range, they must be without any clinical significance
- •8. Have no clinically significant diseases captured in the medical history or evidence of clinically significant findings on physical examination and/or clinical laboratory evaluations (hematology, biochemistry, ECG and urinalysis)
排除标准
- •1. History of significant hypersensitivity to trimebutine, to sulfur containing drugs (e.g. Captopril) or any related products (including excipients of the formulation) as well as severe hypersensitivity reactions (like angioedema) to any drugs
- •2. Presence of significant gastrointestinal, liver/kidney disease, or any other conditions known to interfere with the absorption, distribution, metabolism or excretion of drugs or known to potentiate or predispose to undesired effects
- •3. History of significant gastrointestinal, liver or kidney disease that may affect drug bioavailability
- •4. Presence of significant cardiovascular, pulmonary, hematologic, neurological, psychiatric, endocrine, immunologic or dermatologic disease
- •5. Suicidal tendency, history of or disposition to seizures, state of confusion, clinically relevant psychiatric diseases
- •6. Presence of out-of-range cardiac interval (PR < 110 msec, PR > 200 msec, QRS <60 msec, QRS >110 msec and QTc > 440 msec) on the screening ECG or other clinically significant ECG abnormalities
- •7. Known presence of rare hereditary problems of galactose and /or lactose intolerance
- •8. Use of cysteine, methionine, and other sulfur containing amino acid supplements in the previous 7 days before day 1 of this study
- •9. Maintenance therapy with any drug, or significant history of drug dependency or alcohol abuse (> 3 units of alcohol per day, intake of excessive alcohol, acute or chronic)
- •10. Any clinically significant illness in the previous 28 days before day 1 of this study
- •11. Use of any enzyme-modifying drugs, including strong inhibitors of cytochrome P450 (CYP) enzymes (such as cimetidine, fluoxetine, quinidine, erythromycin, ciprofloxacin, fluconazole, ketoconazole, diltiazem and HIV antivirals) and strong inducers of CYP enzymes (such as barbiturates, carbamazepine, glucocorticoids, phenytoin, rifampin and St John's Wort), in the previous 28 days before day 1 of this study
- •12. Any history of tuberculosis and/or prophylaxis for tuberculosis
- •13. Positive urine screening of ethanol and/or drugs of abuse
- •14. Positive results to HIV, HBsAg or anti-HCV tests
- •15. Females who are pregnant according to a positive serum pregnancy test
- •16. Volunteers who took an Investigational Product (in another clinical trial) or donated 50 mL or more of blood in the previous 28 days before day 1 of this study
研究者
相似试验
已完成
不适用
A phase 1 double blind, placebo controlled study of ALX-0141 single dose subcutaneous administration in healthy post-menopausal womeBone loss10005959NL-OMON32748Ablynx N.V.42
进行中（未招募）
1 期
A Phase 2a, double blind, placebo controlled study to evaluate the efficacy of MEDI-563 in subjects with moderate to severe COPD and sputum eosinophiliaEUCTR2010-020127-52-DKAstraZeneca AB90
进行中（未招募）
不适用
A Phase 2a, double blind, placebo controlled study to evaluate the efficacy of MEDI-563 in subjects with moderate to severe COPD and sputum eosinophiliaChronic obstructive pulmonary disease and Sputum EosinophiliaMedDRA version: 13.1Level: LLTClassification code 10010952Term: COPDSystem Organ Class: 10038738 - Respiratory, thoracic and mediastinal disordersEUCTR2010-020127-52-DEAstraZeneca AB90
进行中（未招募）
1 期
A Phase 2a, double blind, placebo controlled study to evaluate the efficacy of MEDI-563 in subjects with moderate to severe COPD and sputum eosinophiliaEUCTR2010-020127-52-GBAstraZeneca AB101
进行中（未招募）
1 期
A phase I/II, double-blind, placebo-controlled study assessing the safety and efficacy of AVX-012 ophthalmic solution in subjects with mild-to-moderate dry eye syndromeMedDRA version: 20.0 Level: LLT Classification code 10013777 Term: Dry eye syndrome System Organ Class: 100000004853Dry eye syndromeEUCTR2016-001022-34-ESAVIZOREX PHARMA, S.L.172